Abstract
This analysis describes the prevalence of contraindications to nirmatrelvir/ritonavir among 66 007 patients with coronavirus disease 2019 in a large health care system. A possible contradiction was present in 9830 patients (14.8%), with the prevalence of contraindications increasing with higher acuity of illness.
| Original language | English (US) |
|---|---|
| Article number | ofac389 |
| Journal | Open Forum Infectious Diseases |
| Volume | 9 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 1 2022 |
Bibliographical note
Publisher Copyright:© 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- COVID-19
- Palovid
- contraindications
- nirmatrelvir/ritonavir
Fingerprint
Dive into the research topics of 'Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS